Natera tests processed in Q3
Short Answer
Both the model and the market align on Above 1025000, seeing no actionable edge. Natera management does not expect Q3 2026 test volume to set a new record high, implying it will be below the Q2 2026 record of 1,043,900 tests.
1. Executive Verdict
- Q3 2026 test volumes are expected at or below 1,025,000 tests.
- Natera management stated Q3 volume will not exceed the Q2 2026 record.
- Raised revenue guidance and recent approvals may support volume, but not a record.
Who Wins and Why
| Outcome | Market | Model | Why |
|---|---|---|---|
| Above 1025000 | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 1050000 | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 1075000 | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 1100000 | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
| Above 1125000 | 0.0% | 0.0% | Research does not highlight strong supporting evidence. |
Current Context
Natera's Q3 2026 results are pending as of mid-August. The company's third-quarter 2026 financial results have not been released as of August 13, 2026 [^][^][^]. Natera most recently reported its Q2 2026 performance on August 6, 2026 [^][^][^]. For Q2 2026, Natera processed approximately 1,043,900 tests and reported total revenues of $752.8 million [^][^][^].
Recent approvals and study progress support Natera's raised revenue guidance. Following strong Q2 performance, Natera raised its full-year 2026 revenue guidance to a range of $2.85 billion–$2.91 billion [^][^]. The company expects to complete enrollment for its pivotal FIND study in early cancer detection by Q3 2026 [^][^]. Recent milestones include FDA approval for Signatera CDx in bladder cancer in May 2026, PMDA approval for Signatera in colorectal cancer in Japan in June 2026, and EU IVDR certification for Signatera in July 2026 [^][^][^].
2. Market Behavior & Price Dynamics
Historical Price (Probability)
Outcome probability
Date
This market shows extremely limited activity and price discovery. With only five data points recorded on a single day, August 13, 2026, the price has moved sideways between 1.0% and 4.0%, despite a wider bid-ask range of 1.0% to 49.0%. The chart indicates zero traded contracts. This absence of volume means the price does not reflect any executed trades or market consensus. Instead, the price movement represents shifts in unfilled bids and offers on an empty order book.
The lack of activity suggests the market has not yet reacted to Natera's Q2 2026 financial results, which were reported on August 6, 2026. With Q3 2026 results still pending, there is no new catalyst from the provided context to drive trading. Because no capital has been committed, it is not possible to identify meaningful support or resistance levels.
The market sentiment is effectively unformed. While the current 4.0% probability implies a low expectation that Natera will process over 1,025,000 tests in Q3, this reading carries no weight without trading volume to validate it. The market is dormant, likely awaiting further corporate disclosures or fundamental developments before participants are willing to take positions.
3. Significant Price Movements
Notable price changes detected in the chart, along with research into what caused each movement.
📈 August 13, 2026: 14.0pp spike
Price increased from 1.0% to 15.0%
Outcome: Above 1075000
What happened: There is no evidence of social media activity serving as a primary driver for the 14.0 percentage point prediction market spike on August 13, 2026. The most likely driver was the continued positive sentiment following Natera's Q2 2026 earnings report, released on August 6, 2026 [^][^]. Although Natera processed 1,043,900 tests in Q2 [^][^] (below the 1,075,000 threshold), the earnings announcement caused Natera's stock to rally significantly and reach new 52-week highs, attributed to expectations of future growth and the "Signatera scale" showing up [^][^]. This strong traditional news appears to have fueled increased optimism in the Q3 prediction market, making social media irrelevant.
4. Market Data
Contract Snapshot
This market resolves YES if Natera officially reports processing a number of tests in Q3 that exceeds the specific threshold stated in the contract (e.g., Above 1,075,000 tests). Conversely, a NO resolution occurs if the reported number of tests is equal to or below that threshold. Trading for these contracts ends on November 5, 4:00 PM EST, with settlement based on Natera's official Q3 test processing figures.
Available Contracts
Market options and current pricing
| Outcome bucket | Yes (price) | No (price) | Last trade probability |
|---|---|---|---|
| Above 1025000 | $0.98 | $0.96 | 0% |
| Above 1050000 | $0.98 | $0.96 | 0% |
| Above 1075000 | $0.98 | $0.85 | 0% |
| Above 1100000 | $0.96 | $0.98 | 0% |
| Above 1125000 | $0.96 | $0.98 | 0% |
Market Discussion
Natera management indicated they do not expect to set a new volume record in Q3 2026, advising a linear growth model for Signatera volume forecasting rather than extrapolating prior record-setting performance [^][^][^]. This guidance follows strong Q2 2026 earnings and a raised full-year 2026 revenue outlook, which spurred positive sentiment among traders focusing on operational scale and profitability [^][^][^][^]. For historical context, Natera reported approximately 893,600 tests processed in Q3 2025 [^][^][^][^][^][^].
5. Trader Dashboard
A deterministic, per-market integrity scorecard computed from order-book and price data. Higher is better for Trader Trust, Liquidity, Move Quality and Resolution; higher means more risk for Quote Risk and Avoid Risk.
Above 1025000PrimaryTrader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 1050000Trader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 1075000Trader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 1100000Trader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
Above 1125000Trader Trust—Liquidity—Move Quality—Resolution—Quote Risk—Avoid Risk—
Move Quality—No significant move
- Factor
trader_dashboard_lean_v1.13 · computed Aug 13, 2026
6. What is the anticipated commercial impact of Natera's recent FDA, PMDA, and EU IVDR approvals on its Q3 2026 test volumes?
| FDA Approval (Signatera CDx) | May 2026 [^][^][^] |
|---|---|
| PMDA Approval (Colorectal Cancer) | June 2026 [^][^][^] |
| EU IVDR Certification | July 2026 [^][^] |
Natera's recent approvals are set to boost Q3 2026 adoption. The company achieved significant regulatory milestones, including FDA approval for Signatera CDx in May 2026 and Japanese PMDA approval for colorectal cancer in June 2026 [^][^][^]. These approvals are anticipated to drive clinical adoption during Q3 2026, partly due to a 'halo effect' [^][^]. Additionally, Natera announced EU IVDR certification in July 2026 [^][^].
Management expects strong oncology contributions but varied regional impacts. Natera's leadership updated its 2026 annual revenue guidance in August 2026, reflecting these developments and anticipating continued volume growth with strong contributions from oncology [^][^]. While the PMDA approval is expected to encourage adoption, its substantial impact on Japanese test volumes is not foreseen until a commercial launch by year-end 2026, contingent on final reimbursement [^][^]. The direct commercial impact of the EU IVDR certification on Q3 2026 test volumes was not detailed in the provided information [^][^].
7. How does Natera's projected Q3 2026 test volume growth compare to the recent performance of key competitors like Invitae and Myriad Genetics?
| Q2 2026 Test Volume | 1.04 million tests (Natera) [^][^][^] |
|---|---|
| Q2 2026 Year-over-Year Growth | Over 22% (Natera) [^][^][^] |
| FY 2026 Revenue Guidance | $2.85 billion–$2.91 billion (Natera) [^][^] |
Natera recently reported significant test volume growth and increased revenue guidance. The company processed a record 1.04 million tests in Q2 2026, demonstrating over 22% year-over-year growth [^][^][^]. Following this strong performance, Natera raised its full-year 2026 revenue guidance in August 2026 to $2.85 billion–$2.91 billion, citing sustained volume momentum and significant contributions from its oncology segment [^][^]. While Natera's management typically uses a rolling four-quarter average for modeling future growth, acknowledging potential quarter-to-quarter variability, the provided research does not include a specific projected Q3 2026 test volume growth for the company [^][^].
Competitor data is insufficient to allow for a meaningful comparison. A direct comparison of Natera's projected Q3 2026 test volume growth against key competitors like Invitae and Myriad Genetics is not possible with the available information. Invitae is no longer considered a relevant competitor for a direct Q3 2026 performance comparison due to its considerable financial difficulties and delisting [^][^]. Moreover, the provided research lacks any recent performance data or growth projections for Myriad Genetics or other potential competitors. Therefore, the facts are insufficient to compare Natera's projected Q3 2026 test volume growth with the recent performance of its key competitors.
8. What historical quarterly trends and seasonality patterns exist in Natera's test processing volumes from 2024 through Q2 2026?
| Q1 2024 Test Volume | ~720 thousand tests [^][^][^][^][^][^][^] |
|---|---|
| Q4 2025 Test Volume | 923.6 thousand tests [^][^][^][^][^][^][^] |
| Q2 2026 Test Volume | 1,043.9 thousand tests [^][^][^][^][^][^][^] |
Natera's test volumes showed consistent growth from early 2024 to late 2025. Natera's test processing volumes demonstrated a consistent upward trend from the first quarter of 2024 through the end of 2025. Starting at approximately 720 thousand tests in Q1 2024, volumes increased to 792.8 thousand by Q4 2024 [^][^][^][^][^][^][^]. This growth extended into 2025, with volumes reaching approximately 855 thousand in Q1 and concluding the year at 923.6 thousand in Q4 2025 [^][^][^][^][^][^][^].
Test volumes peaked in Q2 2026, with unusual quarterly fluctuations. The upward trajectory in test volumes continued into 2026, reaching approximately 1,014 thousand tests in Q1 and a record-breaking 1,043.9 thousand in Q2 [^][^][^][^][^][^][^]. Natera's women's health test volume typically exhibits seasonality, with Q1 often being the strongest, Q2 the slowest, and recovery occurring in the latter half of the year [^][^]. While 2025 generally adhered to this pattern, the record sequential growth observed in Q2 2026 was described by Natera management as "exaggerated," partly due to recovery from weather impacts experienced in Q1 2026 [^][^][^][^][^][^][^][^]. Following this Q2 high, management does not anticipate a new volume record in Q3 2026 [^].
9. Based on Natera's revised full-year 2026 revenue guidance, what is the implied range for test volumes in the second half of the year?
| Revised 2026 Revenue Guidance | $2.85 billion to $2.91 billion (August 6, 2026 [^][^][^]) |
|---|---|
| Increase in Guidance Midpoint | $100 million (August 6, 2026 [^][^][^]) |
| Test Volume Guidance (H2 2026) | No specific numerical range provided [^][^] |
Natera updated its full-year 2026 revenue guidance, anticipating significant growth. On August 6, 2026, Natera revised its full-year 2026 revenue outlook to a new range of $2.85 billion to $2.91 billion [^][^][^]. This update reflects a $100 million increase at the midpoint compared to the company's prior guidance [^][^][^]. Management attributed this upward revision to an expected meaningful growth during the second half of 2026, which is projected to be fueled by anticipated volume expansion and stable average selling prices for the remainder of the year [^].
Natera did not specify test volume ranges for the second half. Despite the revised revenue figures, Natera did not issue a specific numerical range for test volumes for either the second half of 2026 or the third quarter of 2026 [^]. Company management explicitly indicated that they do not foresee achieving a new volume record in Q3 2026, following the record-breaking performance in Q2 2026 [^][^]. Consequently, the available information is insufficient to determine the implied range for test volumes during the second half of the year.
10. How might the expected completion of enrollment for the FIND study in Q3 2026 affect Natera's reported test volumes for that same quarter?
| FIND Study Enrollment Completion | Q3 2026 (on track) [^][^][^][^][^] |
|---|---|
| Impact on Commercial Volumes | No direct impact on reported commercial 'tests processed' [^][^] |
| R&D Spending Guidance | Maintained for 2026, focused on next phase of ECD program [^][^][^] |
The completion of Natera's FIND study enrollment will not impact commercial volumes. The FIND Early Cancer Detection (ECD) study, expected to complete enrollment in Q3 2026, is categorized as a clinical trial rather than a commercial diagnostic test [^][^]. Consequently, its completion is not anticipated to directly affect the company's reported commercial 'tests processed' volumes for that quarter [^][^].
FIND study completion is an R&D milestone, not a volume driver. While the on-track completion of enrollment for the FIND study represents a significant milestone in Natera's research and development and regulatory roadmap, it does not contribute to commercial test volumes [^][^][^][^][^][^]. Natera's reported commercial test volumes are primarily driven by its established clinical business segments, including oncology (Signatera), women's health, and organ health, rather than clinical trial enrollments [^][^][^][^].
Management confirmed R&D spending for the ECD program's next phase. Natera's management has affirmed its research and development spending guidance for 2026, aligning resources to transition to the subsequent phase of the ECD program [^][^][^]. This includes crucial data analysis and preparations for a planned FDA submission for the early cancer detection program in 2027 [^][^][^].
11. What Could Change the Odds
Key Catalysts
Natera's Q3 2026 earnings are expected in early November 2026, with estimates commonly pointing to November 4 or November 11, 2026 [^] [^] [^] . (NTRA) Earnings Dates, Call Summary & Reports - TipRanks.com" data-source-lanes="traditional">[^][^][^]. However, publicly available information or financial reporting regarding a company named Natera concerning Q3 2026 financial metrics or test volumes is not present in the research, as search results exclusively identified professional athletes [^][^][^][^][^][^].
Following a strong Q2 2026, where Natera processed approximately 1.044 million tests, the company raised its full-year 2026 revenue guidance to $2.85 billion–$2.91 billion [^] [^] [^] . Key bullish catalysts include continued adoption and NCCN guideline inclusion of Signatera, expanded Medicare and private payer reimbursement, and international expansion [^][^][^].
Key Dates & Catalysts
- Expiration: March 05, 2027
- Closes: March 05, 2027
12. Decision-Flipping Events
- Trigger: Natera's Q3 2026 earnings are expected in early November 2026, with estimates commonly pointing to November 4 or November 11, 2026 [^] [^] [^] .
- Trigger: However, publicly available information or financial reporting regarding a company named Natera concerning Q3 2026 financial metrics or test volumes is not present in the research, as search results exclusively identified professional athletes [^] [^] [^] [^] [^] [^] .
- Trigger: Following a strong Q2 2026, where Natera processed approximately 1.044 million tests, the company raised its full-year 2026 revenue guidance to $2.85 billion–$2.91 billion [^] [^] [^] .
- Trigger: Key bullish catalysts include continued adoption and NCCN guideline inclusion of Signatera, expanded Medicare and private payer reimbursement, and international expansion [^] [^] [^] .
14. Historical Resolutions
No historical resolution data available for this series.
